ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0358

Residual’ Fatigue and Its Severity in Patients with Rheumatoid Arthritis in Clinical Remission: Prevalence and Associated Factors

Rosa Maria Morlà Novell1, Beatriz Frade-Sosa2, Lola Tobalina Maestre3, Meritxell Sallés Lizarzaburu4, Virginia Ruiz-Esquide2, Maria López Lasanta5, Georgina Salvador Alarcón6, Noemí Busquets Pérez7, Marta Valls Roc8, Enrique Gonzalez Dávila9, Jose Alfredo Gomez-Puerta10 and Raimon Sanmartí Sala10, and ARCat study Group, 1Hospital Clínic de Barcelona, Barcelona, Spain, 2Hospital Clinic de Barcelona, Barcelona, Spain, 3Fundació Clinic per la Recerca clínica, Barcelona, Spain, 4Althaia Xarxa Assistencial Universitària Manresa, Manresa, Catalonia, Spain, 5Hospital Universitari Vall d´Hebron, Rheumatology, Barcelona, Spain, 6Hospital Mútua de Terrassa, Terrassa, Spain, 7HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, 8Hospital Universitari Josep Trueta, Girona, 9Universidad de La Laguna, Santa Cruz de Tenerife, Spain, 10Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain

Meeting: ACR Convergence 2024

Keywords: Fatigue, Measurement Instrument, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Patient Outcomes, Preferences, & Attitudes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Fatigue is a frequent and annoying symptom in rheumatoid arthritis (RA) patients that is often not assessed at routine follow-up visits. Residual’ fatigue has been described in patients in remission or with low clinical activity, measured with the VAS_Fatigue, at 2 different cut-off points: >2 (presence) and >5 (high level) (1,2).
We study the prevalence and clinical, sociodemographic, laboratory, self-reported patients and therapies associated with fatigue in established RA patients in clinical remission and we compared whether these factors differs according to the severity of fatigue.

Methods: Patients with RA (ACR criteria, 2010), excluding Chronic Fatigue Syndrome, were consecutively collected during periodic visits to different Rheumatology Services distributed throughout the geography of Catalonia (ARCat study group) for 6 months. The patients studied are those in strict clinical remission (DAS28 < 2.6). They were divided into two groups: group F2=fatigue is considered if VAS_Fatigue>2, and group F5=fatigue is considered if VAS_Fatigue>5).

We studied sociodemographics, disease variables (erosive, disease evolution), comorbidities, clinical disease activity (TJC28, SJC28, CDAI, SDAI, and DAS28CRP), laboratory markers (RF, ACPA ESR, and CRP), drug therapy (glucocorticoids or DMARDs) and those obtained from the questionnaires (1.MDHAQ which includes: PGA, VAS_Pain, VAS_Fatigue, Review of 60 symptoms (ROS60), and the integrated indices: RAPID3 (0-30) for activity disease, FAST3 and FAST4 for fibromyalgia, and MSD2 for depression; 2. Global FACIT-Fatigue global; 3. Global RAID).

An univariate analysis of the different factors analyzed were studied according to the degree of fatigue (group F2 and group F5).

Results: Of a total of 243 patients recruited, 39.1% (n=95) were in clinical remission (DAS28ESR< 2.6). The prevalence of ‘residual’ fatigue in F2 is 55,4% (n=51) and in F5 is 19,5% (n=18). 
Most of the studied variables associated with fatigue were similar in both groups (F2 and F5). Statistical sexes differences (females, more affected) were observed only in F2. Higher rates of associated osteoarthritis and depression were observed in patients with fatigue in the F2 group, but not in F5 group. Interestingly a positive association with the different clinical activity indices and fatigue were observed in both groups. However, the joint count (TJC28 and SJC28) and ESR were associated with fatigue only in F5. VAS_Pain was higher in fatigated patients of both groups. Significative differences were found for all of the self-reported MDHAQ items (including RAPID3, FAST3, FAST4, and MSD2), RAID global, and FACIT-Fatigue global in both groups (F2 and F5). (Table 1 and 2; only variables with statistical significative differences).

Conclusion: Residual´ fatigue should be taken into account because of its prevalence in RA patients in strict clinical remission. Similar clinical factors are associated in the study with mild and severe fatigue, but inflammatory activity seems to play an important role in cases of severe fatigue.


References:

1.Tournadre A, et al. Joint Bone Spine 2019. 
2.Pollard L.C, et al. Rheumatology 2006.

Supporting image 1

Supporting image 2


Disclosures: R. Morlà Novell: None; B. Frade-Sosa: None; L. Tobalina Maestre: None; M. Sallés Lizarzaburu: None; V. Ruiz-Esquide: None; M. López Lasanta: None; G. Salvador Alarcón: None; N. Busquets Pérez: None; M. Valls Roc: None; E. Gonzalez Dávila: None; J. Gomez-Puerta: AstraZeneca, 6, Boehringer-Ingelheim, 6, Eli Lilly, 6, GlaxoSmithKlein(GSK), 6, Janssen, 6, Otsuka, 6; R. Sanmartí Sala: None.

To cite this abstract in AMA style:

Morlà Novell R, Frade-Sosa B, Tobalina Maestre L, Sallés Lizarzaburu M, Ruiz-Esquide V, López Lasanta M, Salvador Alarcón G, Busquets Pérez N, Valls Roc M, Gonzalez Dávila E, Gomez-Puerta J, Sanmartí Sala R. Residual’ Fatigue and Its Severity in Patients with Rheumatoid Arthritis in Clinical Remission: Prevalence and Associated Factors [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/residual-fatigue-and-its-severity-in-patients-with-rheumatoid-arthritis-in-clinical-remission-prevalence-and-associated-factors/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/residual-fatigue-and-its-severity-in-patients-with-rheumatoid-arthritis-in-clinical-remission-prevalence-and-associated-factors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology